#CRDF

1 month ago

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selection of 30 mg onvansertib dose for registrational

#CRDF Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

www.stocktitan.net/news/CRDF/cardiff-oncolo...

0 0 0 0

Oninvest

@oninvest.bsky.social

2 months ago

Noble analysts named a micro-cap stock with growth potential of more than 320% – Oninvest Shares in biotech company Cardiff Oncology, which has a market capitalization of just $191 million on Nasdaq, have the potential to grow more than fourfold relative to their current price, according t...

#CRDF could surge 4x+, per Noble Capital Markets, which initiated coverage with Outperform and a $12 target vs $2.84. Analysts point to positive interim data for onvansertib, a therapy for hard-to-treat colorectal cancer. Updated data due Q1 2026. en.oninvest.com/article/nobl...

0 0 0 0

InsiderFinance

@insiderfinance.com

2 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CRDF, #CIB, #ZVRA, #NKLR, #CXW

#OptionFlow #OptionsTrading #Trading

0 0 0 0

John Vandermosten

@vanjohn10.bsky.social

2 months ago

Zacks Initiation on Cardiff Oncology (CRDF) YouTube video by Unboxing Biotech

We initiated on Cardiff Oncology with an $8.50 price target.
youtu.be/_pV9tsv2h8Y
See our report at the link below:
s27.q4cdn.com/906368049/fi...
#CardiffOncology #CRDF #Biotech #Oncology

0 0 0 0

Zacks Small Cap Research

@zackssmallcap.bsky.social

3 months ago

#CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response buff.ly/c12l2Um

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 Cardiff Oncology (Nasdaq: CRDF) announced clinical data from an investigator-sponsored Phase 1 poster on onvansertib in chronic myelomonocytic leukemia (CMML) to be presented at ASH 2025.In a dose-escalation trial (N=9), onvansertib monotherapy was reported as relatively well-tolerated and showed preliminary efficacy in approximately 40% of patients, with one patient achieving an optimal marrow response at the 9 mg/m2 dose. The company is not currently planning to develop onvansertib for CMML.Poster details: Dec 8, 2025, 6:00-8:00 PM EST; Speaker: Mrinal Patnaik, MD; Session 637, Poster III.

#CRDF Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

www.stocktitan.net/news/CRDF/cardiff-oncolo...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

#CRDF Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

www.stocktitan.net/news/CRDF/cardiff-oncolo...

0 0 0 0

Market Wire News

@marketwirenews.com

7 months ago

Just In: ( NASDAQ: #CRDF ) Expected earnings - Cardiff Oncology Inc.

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update Cardiff Oncology (Nasdaq: CRDF) announced Q2 2025 financial results and significant clinical progress. The company completed enrollment in its randomized Phase 2 CRDF-004 trial for onvansertib plus standard of care in first-line RAS-mutated metastatic colorectal cancer. Key highlights include the appointment of Dr. Roger Sidhu as Chief Medical Officer and positive data from a Phase 1b trial showing 40% objective response rate for onvansertib with paclitaxel in metastatic triple negative breast cancer.Financially, Cardiff reported $71.0 million in cash and investments as of June 30, 2025, with a projected runway into Q1 2027. Q2 operating expenses increased to $14.9 million, up from $12.7 million year-over-year, primarily due to clinical trial costs and personnel expenses. The company also secured a new USPTO patent for onvansertib treatment in mCRC, extending protection until 2043.

#CRDF Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update

www.stocktitan.net/news/CRDF/cardiff-oncolo...

0 0 0 0

InsiderFinance

@insiderfinance.com

7 months ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #GPRO 103% OTM
2. #BITF 61% OTM
3. #VLN 56% OTM
4. #OKLO 43% OTM
5. #CRDF 43% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

InsiderFinance

@insiderfinance.com

7 months ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#GPRO, #BITF, #VLN, #CRDF, #OKLO

#OptionFlow #OptionsTrading #Trading

0 0 0 0

InsiderFinance

@insiderfinance.com

8 months ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#MSTR, #NA, #WOLF, #CRDF, #CLBR

#OptionFlow #OptionsTrading #Trading

0 0 0 0

InsiderFinance

@insiderfinance.com

8 months ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MSTR 107% OTM
2. #NA 83% OTM
3. #TSLA 66% OTM
4. #WOLF 65% OTM
5. #CRDF 46% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

InsiderFinance

@insiderfinance.com

8 months ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#WOLF, #CRDF, #ETHE, #UNH, #SATS

#OptionFlow #OptionsTrading #Trading

0 0 0 0

InsiderFinance

@insiderfinance.com

8 months ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #WOLF 65% OTM
2. #CRDF 46% OTM
3. #MU 34% OTM
4. #CRCL 26% OTM
5. #ETHE 26% OTM

#OptionFlow #OptionsTrading #Trading